维拉帕米联合化疗药物靶动脉灌注治疗中晚期非小细胞肺癌的疗效
该研究纳入60例中晚期非小细胞肺癌患者,比较靶动脉灌注维拉帕米联合化疗药物(研究组26例)与单纯靶动脉灌注化疗药物(对照组34例)的疗效。结果显示研究组近期有效率、疾病控制率、KPS评分及生存期均优于对照组,但CD4+水平及CD4+/CD8+比值低于对照组,两组不良反应无显著差异。
要点
- 维拉帕米联合化疗靶动脉灌注可提高中晚期NSCLC近期疗效和疾病控制率。
- 联合方案可降低血清CEA和CA50水平,改善KPS评分并延长生存期。
- 联合方案对免疫功能有一定抑制作用,CD4+水平及CD4+/CD8+比值降低。
核心结论
- 靶动脉灌注维拉帕米联合化疗药物可有效提高中晚期NSCLC的近期疗效,降低血清肿瘤标志物水平,提高生活质量并延长生存时间,但对机体免疫功能有一定抑制作用。
研究设计与样本
- 回顾性队列研究,纳入2016年4月至2018年4月驻马店市中心医院收治的60例中晚期NSCLC患者,研究组26例采用靶动脉灌注维拉帕米及化疗药物,对照组34例采用靶动脉灌注化疗药物,均连续治疗2个月以上。
主要发现
- 研究组治疗有效率和疾病控制率分别为80.8%和96.2%,高于对照组的55.9%和76.5%(P<0.05)。
- 治疗后研究组CD4+水平为(25.43±2.76)%、CD4+/CD8+为0.88±0.11,低于对照组的(27.56±2.79)%和0.95±0.13(P<0.05)。
- 治疗后研究组血清CEA和CA50水平分别为(11.57±2.32)ng/ml和(16.62±3.28)U/ml,低于对照组的(15.87±2.66)ng/ml和(20.31±3.42)U/ml(P<0.05)。
- 两组各不良反应发生率差异均无统计学意义(P>0.05)。
- 研究组治疗后KPS评分为(81.44±2.76)分,高于对照组的(79.62±2.38)分(P<0.05);中位生存时间和中位无进展生存时间分别为16.0个月和7.5个月,优于对照组的10.0个月和5.0个月(P<0.05)。
临床怎么用
- 对于中晚期NSCLC患者,可考虑靶动脉灌注维拉帕米联合化疗药物以提高近期疗效和生存获益,但需监测免疫功能抑制情况。
局限性
- 研究为单中心小样本回顾性分析,分组非随机,样本量有限,结论需前瞻性大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the effects of targeted artery perfusion of verapamil and chemotherapy drugs on advanced non-small cell lung cancer (NSCLC). Methods: Sixty patients with advanced NSCLC who were admitted to the Central Hospital of Zhumadian from April 2016 to April 2018 were selected as the research subjects. They were divided into the observation group (26 cases) and the control group (34 cases) according to the treatment method. Patients in the observation group were treated with targeted artery perfusion of verapamil and chemotherapy drugs while the control group were treated with target artery perfusion of chemotherapy drugs alone.Both groups were treated continuously for more than 2 months. The short-term curative effect, adverse reactions, changes in immune function, levels of serum tumor markers and Karnofsky Performance Scale (KPS) scores before and after treatment as well as the prognosis were compared between the two groups. Results: The response rate and control rate in the observation group were 80.8% and 96.2%, higher than 55.9% and 76.5% in the control group (P<0.05). After treatment, CD4(+) levels and CD4(+) /CD8(+) in the observation group were (25.43±2.76)% and (0.88±0.11), lower than (27.56±2.79)% and (0.95±0.13) in the control group (P<0.05). After treatment, serum levels of CEA and CA50 in the observation group were (11.57±2.32)ng/ml and (16.62±3.28)U/ml, also lower than (15.87±2.66)ng/ml and (20.31±3.42)U/ml in the control group (P<0.05). There was no significant difference in adverse reactions between the two groups (P>0.05). After treatment, KPS score of the observation group was (81.44±2.76) points, higher than (79.62±2.38) points of the control group (P<0.05). The median survival time and progression-free median survival time of the observation group were 16.0 months and 7.5 months, respectively, significantly better than 10.0 months and 5.0 months of the control group (P<0.05). Conclusions: The treatment with target arterial perfusion of verapamil and chemotherapy drugs for advanced NSCLC can effectively improve the short-term curative effect, reduce serum levels of tumor markers, improve life quality and prolong the survival time. However, it has a certain inhibitory effect on the patient's immune function. 目的: 探讨靶动脉灌注维拉帕米和化疗药物治疗中晚期非小细胞肺癌(NSCLC)的疗效。 方法: 以2016年4月至2018年4月间驻马店市中心医院收治的60例中晚期NSCLC为研究对象,根据治疗方法的不同将患者分为研究组(26例)和对照组(34例),研究组患者采用靶动脉灌注维拉帕米及化疗药物治疗,对照组患者采用靶动脉灌注化疗药物治疗,均连续治疗2个月以上,比较两组患者的近期疗效、不良反应,治疗前后免疫功能、血清肿瘤标志物水平、卡氏功能状态(KPS)评分的变化,以及预后。 结果: 研究组患者的治疗有效率和疾病控制率分别为80.8%和96.2%,均明显高于对照组(分别为55.9%和76.5%,均P<0.05)。治疗后,研究组患者的CD4(+)水平为(25.43±2.76)%、CD4(+)/CD8(+)为0.88±0.11,均明显低于对照组[分别为(27.56±2.79)%和0.95±0.13,均P<0.05]。治疗后,研究组患者的血清癌胚抗原(CEA)和糖类抗原50(CA50)水平分别为(11.57±2.32)ng/ml和(16.62±3.28)U/ml,均明显低于对照组[分别为(15.87±2.66)ng/ml和(20.31±3.42)U/ml,均P<0.05]。两组各不良反应的发生率比较,差异均无统计学意义(P>0.05)。治疗后,研究组患者的KPS评分为(81.44±2.76)分,明显高于对照组[(79.62±2.38)分,P<0.05]。研究组患者的中位生存时间和中位无进展生存时间分别为16.0和7.5个月,对照组患者的中位生存时间和中位无进展生存时间分别为10.0和5.0个月,研究组生存情况明显优于对照组(P<0.05)。 结论: 中晚期NSCLC患者采用靶动脉灌注维拉帕米和化疗药物治疗,可有效提高近期疗效,降低血清肿瘤标志物水平,提高生活质量,延长生存时间,但对患者机体免疫功能具有一定抑制作用。.
引用
- Tan YF, Ma HX, Zhao B, et al. [Therapeutic effects of target artery infusion of verapamil and chemotherapy drugs on advanced non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32575945. doi:10.3760/cma.j.cn112152-20190724-00461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。